Researchers identify best drug therapy for rare, aggressive pancreatic cancer June 10, 2016 Overview Show transcript Overview Each year, about 200 to 400 Americans develop acinar cell carcinoma, a rare form of pancreatic cancer that has no effective standard of care. John A. Copland III, Ph.D., discusses a study involving researchers on Mayo Clinic's campuses in Jacksonville, Florida, and Rochester, Minnesota, who found that the chemotherapy drug oxaliplatin is effective in stopping the growth of this cancer. Share Doximity Facebook LinkedIn Twitter Print details Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleDevelopment of new surgical procedures and predictors of outcome for patients with advanced pancreatic cancer VID-20439992 Medical Professionals Researchers identify best drug therapy for rare, aggressive pancreatic cancer